Article Sidebar

PDF
Date Published: 03/11/2023
Online Published: 20/11/2023
Abstract Views: 85
Views PDF: 89
DOI: https://doi.org/10.58490/ctump.2023i68.2246
Issue
No. 68 (2023)
Section
Article
How to Cite
Pham, T. N., Le, V. T., & Ngo, V. N. (2023). ROLE OF DENOSUMAB IN MANAGEMENT OF GIANT CELL TUMOR OF BONE: A CASE REPORT AND LITERATURE REVIEW. Cantho Journal of Medicine and Pharmacy, 68, 44-51. https://doi.org/10.58490/ctump.2023i68.2246

ROLE OF DENOSUMAB IN MANAGEMENT OF GIANT CELL TUMOR OF BONE: A CASE REPORT AND LITERATURE REVIEW

Thanh Nha Pham1,, Van Tho Le1, Viet Nhuan Ngo2
1 Hospital for Traumatology and Orthopaedics
2 University of Medicine and Pharmacy at Ho Chi Minh City

Main Article Content

Abstract

Denosumab is a relatively new, very promising targeted therapy option for patients with giant cell tumor of bone. It has a role as a neoadjuvant therapy in borderline resectable cases and as a part of multidisciplinary management for primary unresectable lesions or metastases. However, controversies remain regarding the dose and duration of denosumab therapy for different indications, as well as the safety of denosumab relating to side effects, local recurrence, and malignant progression. We used denosumab as a neoadjuvant therapy for two cases to facilitate surgery, and as a long-term treatment for an unresectable giant cell tumor of bone.

Article Details

Keywords

Denosumab, giant cell tumor of bone, unresectable

References

1. Choi J.H, Ro J.Y. The 2020 WHO Classification of Tumors of Bone: An Updated Review. Adv Anat Pathol. 2021.28(3):119-138, doi: 10.1097/PAP.0000000000000293.
2. Noh B.J, Park Y.K. Giant cell tumor of bone: updated molecular pathogenesis and tumor biology. Hum Pathol. 2018.81:1-8, doi: 10.1016/j.humpath.2018.06.017.
3. Wągrodzki M., Tysarowski A., Seliga K., Wojnowska A., Stepaniuk M., Castañeda Wysocka
P., Makuła D., Pieńkowski A., Szostakowski B., Zub R., Rutkowski P. Diagnostic Utility of Genetic and Immunohistochemical H3-3A Mutation Analysis in Giant Cell Tumour of Bone. Int J Mol Sci. 2022.23(2):969, doi: 10.3390/ijms23020969.
4. Singh V.A., Puri A. The current standing on the use of denosumab in giant cell tumour of the bone. J Orthop Surg (Hong Kong). 2020.28(3), doi: 10.1177/2309499020979750.
5. Jiang C.Y., Zhao L., Schuetze S.M., Chugh R. Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications. Oncologist. 2022.27(7):595-599, doi: 10.1093/oncolo/oyac066.
6. Borkowska A.M., Szumera-Ciećkiewicz A., Szostakowski B., Pieńkowski A., Rutkowski P.L.
Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence. Cancers (Basel). 2022.14(9):2290, doi: 10.3390/cancers14092290. PMID: 35565419.
7. Xiang F., Liu H., Deng J., Ma W., Chen Y. Progress on Denosumab Use in Giant Cell Tumor of Bone: Dose and Duration of Therapy. Cancers (Basel). 2022.14(23):5758, doi:
10.3390/cancers14235758.